The Correlation between Inflammation, BPH and Prostate Cancer

European Urology, Supplements

Volumn 8, Issue 13, 2009, Pages 863-864

  Djavan, Bob ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ALTERNATIVE MEDICINE; ANTIANDROGEN THERAPY; ANTIINFLAMMATORY ACTIVITY; BLADDER NECK STENOSIS; DISEASE ASSOCIATION; DRUG MECHANISM; EDITORIAL; HUMAN; INFLAMMATION; LIFE EXPECTANCY; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; URINARY TRACT DISEASE; URODYNAMICS;

EID: 72049133165     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.11.001     Document Type: Editorial

References (13)

1. Habib F.K., and Wyllie M.G. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 7 (2004) 195-200
2. Buck A.C. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 172 (2004) 1792-1799
3. Bayne C.W., Donnelly F., Ross M., and Habib F.K. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 40 (1999) 232-241
4. Di Silverio F., Monti S., Sciarra A., et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 37 (1998) 77-83
5. Marks L.S., Hess D.L., Dorey F.J., Luz Macairan M., Cruz Santos P.B., and Tyler V.E. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 57 (2001) 999-1005
6. Bayne C.W., Ross M., Donnelly F., and Habib F.K. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol 164 (2000) 876-881
7. Habib F.K., Ross M., Ho C.K., Lyons V., and Chapman K. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 114 (2005) 190-194
8. ®) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 33 (1998) 340-347
9. Vacherot F., Azzouz M., Gil-Diez-De-Medina S., et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia. Prostate 45 (2000) 259-266
10. Hill B., and Kyprianou N. Effect of permixon on human prostate cell growth: lack of apoptotic action. Prostate 61 (2004) 73-80
11. Vela Navarrete R., Garcia Cardoso J.V., Barat A., Manzarbeitia F., and López Farré A. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 44 (2003) 549-555
12. Raga A., Ragab-Thomas J.M.F., Delhan A., et al. Effects of Permixon (Sereprostat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. In: Di Silverio F., and Steg A. (Eds). New trends in bladder cancer chemotherapy-new trends in BPH etiopathogenesis (1998), ActaMedica, Rome, Italy 293-296
13. Paubert-Braquet M., Mencia Huerta J.M., Cousse H., and Braquet P. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 57 (1997) 299-304